Articles: disease.
-
The present study aimed to evaluate the radiological findings of coronavirus patients who had positive computed tomography of the lung following real-time reverse transcriptase-polymerase chain reaction testing. The data of 1727 patients who had reverse-transcriptase-polymerase chain reaction (RT-PCR) testing between May 2020 and August 2021 and had thoracic computed tomography (CT) on Days 7th to 8th were analyzed retrospectively. The Radiological Society of North America's recommended reporting system was used to categorize CT findings. ⋯ Thoracic CT is a critical diagnostic tool in Coronavirus Disease 2019 patients with RT-PCR negative. It also depicts the progression of lung involvement in RT-PCR-positive patients. Performing it late in the disease's progression may increase the risk of contracting the disease.
-
Randomized Controlled Trial
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Among patients with resected, epidermal growth factor receptor (EGFR)-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or without previous adjuvant chemotherapy, resulted in significantly longer disease-free survival than placebo in the ADAURA trial. We report the results of the planned final analysis of overall survival. ⋯ Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
-
Randomized Controlled Trial Multicenter Study
Cardiovascular Safety of Testosterone-Replacement Therapy.
The cardiovascular safety of testosterone-replacement therapy in middle-aged and older men with hypogonadism has not been determined. ⋯ In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).